Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.28
IPCM's Cash to Debt is ranked higher than
70% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. IPCM: 0.28 )
IPCM' s 10-Year Cash to Debt Range
Min: 0.26   Max: No Debt
Current: 0.28

Equity to Asset 0.57
IPCM's Equity to Asset is ranked higher than
80% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. IPCM: 0.57 )
IPCM' s 10-Year Equity to Asset Range
Min: -0.67   Max: 0.77
Current: 0.57

-0.67
0.77
Interest Coverage 125.22
IPCM's Interest Coverage is ranked higher than
91% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 6.09 vs. IPCM: 125.22 )
IPCM' s 10-Year Interest Coverage Range
Min: 3.67   Max: 9999.99
Current: 125.22

3.67
9999.99
F-Score: 4
Z-Score: 4.11
M-Score: -2.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.09
IPCM's Operating margin (%) is ranked higher than
78% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 9.44 vs. IPCM: 11.09 )
IPCM' s 10-Year Operating margin (%) Range
Min: 0.57   Max: 11.09
Current: 11.09

0.57
11.09
Net-margin (%) 6.79
IPCM's Net-margin (%) is ranked higher than
81% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 5.38 vs. IPCM: 6.79 )
IPCM' s 10-Year Net-margin (%) Range
Min: -0.46   Max: 6.79
Current: 6.79

-0.46
6.79
ROE (%) 13.14
IPCM's ROE (%) is ranked higher than
82% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. IPCM: 13.14 )
IPCM' s 10-Year ROE (%) Range
Min: -2.02   Max: 13.9
Current: 13.14

-2.02
13.9
ROA (%) 7.53
IPCM's ROA (%) is ranked higher than
89% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. IPCM: 7.53 )
IPCM' s 10-Year ROA (%) Range
Min: -0.89   Max: 9.9
Current: 7.53

-0.89
9.9
ROC (Joel Greenblatt) (%) 124.70
IPCM's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 17.97 vs. IPCM: 124.70 )
IPCM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.79   Max: 248.78
Current: 124.7

4.79
248.78
Revenue Growth (%) 17.10
IPCM's Revenue Growth (%) is ranked higher than
93% of the 180 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. IPCM: 17.10 )
IPCM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 17.6
Current: 17.1

0
17.6
EBITDA Growth (%) 18.20
IPCM's EBITDA Growth (%) is ranked higher than
88% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. IPCM: 18.20 )
IPCM' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 20.5
Current: 18.2

0
20.5
EPS Growth (%) 17.90
IPCM's EPS Growth (%) is ranked higher than
85% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 9.30 vs. IPCM: 17.90 )
IPCM' s 10-Year EPS Growth (%) Range
Min: 0   Max: 26
Current: 17.9

0
26
» IPCM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

IPCM Guru Trades in Q1 2013

Joel Greenblatt 16,960 sh (New)
Steven Cohen 4,966 sh (+599.44%)
Ron Baron 150,275 sh (unchged)
Chuck Royce 99,733 sh (unchged)
» More
Q2 2013

IPCM Guru Trades in Q2 2013

Ron Baron 150,275 sh (unchged)
Chuck Royce 99,733 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 10,302 sh (-39.26%)
» More
Q3 2013

IPCM Guru Trades in Q3 2013

Joel Greenblatt 37,586 sh (+264.84%)
Chuck Royce 99,733 sh (unchged)
Ron Baron 150,000 sh (-0.18%)
» More
Q4 2013

IPCM Guru Trades in Q4 2013

Paul Tudor Jones 4,000 sh (New)
Ron Baron 150,000 sh (unchged)
Chuck Royce 60,129 sh (-39.71%)
Joel Greenblatt 10,618 sh (-71.75%)
» More
» Details

Insider Trades

Latest Guru Trades with IPCM

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Reduce -71.75%0.04%$49.1 - $62.88 $ 48.19-15%10618
Joel Greenblatt 2013-09-30 Add 264.84%0.05%$49.18 - $54.64 $ 48.19-7%37586
Joel Greenblatt 2013-06-30 Reduce -39.26%0.01%$39.33 - $53.38 $ 48.193%10302
Joel Greenblatt 2013-03-31 New Buy0.04%$39.71 - $44.88 $ 48.1912%16960
Joel Greenblatt 2012-03-31 Sold Out 0.08%$30.61 - $45.65 $ 48.1946%0
Joel Greenblatt 2011-12-31 Add 28.55%0.02%$35.32 - $47.54 $ 48.1913%15297
Ron Baron 2011-12-31 Add 20.1%0.01%$35.32 - $47.54 $ 48.1913%151050
Joel Greenblatt 2011-09-30 New Buy0.07%$36.4 - $51.94 $ 48.1913%11900
Joel Greenblatt 2011-06-30 Sold Out 0.1%$44.94 - $52.25 $ 48.190%0
Joel Greenblatt 2011-03-31 New Buy0.1%$37.01 - $45.97 $ 48.1918%6991
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.40
IPCM's P/E(ttm) is ranked higher than
69% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 21.80 vs. IPCM: 20.40 )
IPCM' s 10-Year P/E(ttm) Range
Min: 3.73   Max: 672.37
Current: 20.4

3.73
672.37
P/B 2.50
IPCM's P/B is ranked higher than
58% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 2.29 vs. IPCM: 2.50 )
IPCM' s 10-Year P/B Range
Min: 1.87   Max: 4.59
Current: 2.5

1.87
4.59
P/S 1.40
IPCM's P/S is ranked higher than
53% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.37 vs. IPCM: 1.40 )
IPCM' s 10-Year P/S Range
Min: 0.23   Max: 2.22
Current: 1.4

0.23
2.22
PFCF 25.30
IPCM's PFCF is ranked lower than
60% of the 165 Companies
in the Global Medical Care industry.

( Industry Median: 15.52 vs. IPCM: 25.30 )
IPCM' s 10-Year PFCF Range
Min: 9.62   Max: 43.95
Current: 25.3

9.62
43.95
EV-to-EBIT 13.20
IPCM's EV-to-EBIT is ranked higher than
73% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 17.82 vs. IPCM: 13.20 )
IPCM' s 10-Year EV-to-EBIT Range
Min: 8.6   Max: 20.5
Current: 13.2

8.6
20.5
PEG 1.10
IPCM's PEG is ranked higher than
85% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 2.00 vs. IPCM: 1.10 )
IPCM' s 10-Year PEG Range
Min: 0.64   Max: 1.91
Current: 1.1

0.64
1.91
Shiller P/E 29.20
IPCM's Shiller P/E is ranked lower than
55% of the 105 Companies
in the Global Medical Care industry.

( Industry Median: 24.97 vs. IPCM: 29.20 )
IPCM' s 10-Year Shiller P/E Range
Min: 22.28   Max: 104.26
Current: 29.2

22.28
104.26

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.30
IPCM's Price/DCF (Projected) is ranked higher than
51% of the 122 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. IPCM: 1.30 )
IPCM' s 10-Year Price/DCF (Projected) Range
Min: 1.65   Max: 2.85
Current: 1.3

1.65
2.85
Price/Median PS Value 0.90
IPCM's Price/Median PS Value is ranked higher than
84% of the 206 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. IPCM: 0.90 )
IPCM' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 1.2
Current: 0.9

0.65
1.2
Price/Peter Lynch Fair Value 1.00
IPCM's Price/Peter Lynch Fair Value is ranked higher than
84% of the 58 Companies
in the Global Medical Care industry.

( Industry Median: 1.50 vs. IPCM: 1.00 )
IPCM' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.83   Max: 3.62
Current: 1

0.83
3.62
Earnings Yield (Greenblatt) 7.60
IPCM's Earnings Yield (Greenblatt) is ranked higher than
74% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 5.50 vs. IPCM: 7.60 )
IPCM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.9   Max: 11.6
Current: 7.6

4.9
11.6
Forward Rate of Return (Yacktman) 20.08
IPCM's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 169 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. IPCM: 20.08 )
IPCM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.2   Max: 26.8
Current: 20.08

-3.2
26.8

Business Description

Industry: Health Care Providers » Medical Care
Compare: » details
Traded in other countries:3IP.Germany
IPC The Hospitalist Company, Inc., a Delaware corporation was incorporated in January 1998. The Company is a provider of hospitalist services in the United States. The company's affiliated hospitalists, physicians, nurse practitioners and physician assistants provide hospitalist solutions at hospitals and other inpatient facilities. IPC assists hospitals and customers in improving quality of care, increasing operating efficiencies and reducing costs. As of December 31, 2012, its over 1,410 affiliated hospitalists, including physicians, nurse practitioners and physician assistants (collectively 'affiliated hospitalists') provide hospitalist solutions at over 350 hospitals and 810 other inpatient and post-acute care facilities primarily in 28 states. The company has had 14.1 million patient encounters since the beginning of 2010. Collectively, its affiliated hospitalists work with more than 39,000 referring physicians and 3,920 health plans. In the three years ending December 31, 2011, it has acquired 43 practice groups. The company successfully integrated these acquisitions into IPC and onto its proprietary technology-based practice management system known as IPC-Link. The company, through its affiliated hospitalists, provides, manages and coordinates the care of hospitalized patients and serves as the inpatient partner of primary care physicians and specialists, allowing them to focus their time and resources on their office based practices or their specialties. IPC also provides its affiliated hospitalists with the infrastructure, information management systems, specialized training programs and administrative support necessary to perform these services. IPC generates approximately 95% of its net revenues through its affiliated hospitalists' patient encounters at hospitals and other inpatient facilities including acute, sub-acute and long-term care settings. The company's hospitalist programs are structured to provide acute care hospitals with a consistent on-site physician presence that typically results in fewer admitting physicians overseeing patients in the hospital, thereby reducing process variability and enhancing the ability to implement standardized practices. IPC provides its affiliated hospitalists with access to IPC-Link through its web-based 'Virtual Office' portal to support their clinical, administrative and communications needs. IPC-Link is distinctive in its ability to capture the results of each doctor-patient encounter and organize these results into a searchable database. IPC-Link(r) enables its affiliated hospitalists to view and record important patient data, and allows hospitalists in a practice group to share patient information as needed. The company uses IPC-Link(r) to create customized surveys for patients who are discharged to home from an inpatient facility. To assist in monitoring and documenting the patient's discharge or transition to outpatient care, IPC-Link(r) provides its call center with pati

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide